PT4222149T - Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1- il)-acetamida como inibidores do recetor i do fator de crescimento de transformao beta/alk5 - Google Patents

Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1- il)-acetamida como inibidores do recetor i do fator de crescimento de transformao beta/alk5

Info

Publication number
PT4222149T
PT4222149T PT217861699T PT21786169T PT4222149T PT 4222149 T PT4222149 T PT 4222149T PT 217861699 T PT217861699 T PT 217861699T PT 21786169 T PT21786169 T PT 21786169T PT 4222149 T PT4222149 T PT 4222149T
Authority
PT
Portugal
Prior art keywords
alk5
quinolin
pyrazol
pyridin
inhibitors
Prior art date
Application number
PT217861699T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Agomab Spain S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Spain S L U filed Critical Agomab Spain S L U
Publication of PT4222149T publication Critical patent/PT4222149T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT217861699T 2020-09-30 2021-09-29 Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1- il)-acetamida como inibidores do recetor i do fator de crescimento de transformao beta/alk5 PT4222149T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20382861.1A EP3978487A1 (en) 2020-09-30 2020-09-30 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (1)

Publication Number Publication Date
PT4222149T true PT4222149T (pt) 2026-06-03

Family

ID=72744716

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217861699T PT4222149T (pt) 2020-09-30 2021-09-29 Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1- il)-acetamida como inibidores do recetor i do fator de crescimento de transformao beta/alk5

Country Status (20)

Country Link
US (1) US12577230B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978487A1 (cg-RX-API-DMAC7.html)
JP (1) JP7752684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079027A (cg-RX-API-DMAC7.html)
CN (1) CN116323601B (cg-RX-API-DMAC7.html)
AR (1) AR123543A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021353965A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3196108A1 (cg-RX-API-DMAC7.html)
DK (1) DK4222149T3 (cg-RX-API-DMAC7.html)
ES (1) ES3029607T3 (cg-RX-API-DMAC7.html)
FI (1) FI4222149T3 (cg-RX-API-DMAC7.html)
IL (1) IL301663B2 (cg-RX-API-DMAC7.html)
LT (1) LT4222149T (cg-RX-API-DMAC7.html)
MX (1) MX2023002900A (cg-RX-API-DMAC7.html)
PH (1) PH12023550777A1 (cg-RX-API-DMAC7.html)
PT (1) PT4222149T (cg-RX-API-DMAC7.html)
RS (1) RS68301B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022069509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302393B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
WO2026017797A1 (en) 2024-07-17 2026-01-22 Agomab Spain S.L.U. Crystalline forms
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2009500419A (ja) * 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
IN2014CN02805A (cg-RX-API-DMAC7.html) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Also Published As

Publication number Publication date
US20230373966A1 (en) 2023-11-23
KR20230079027A (ko) 2023-06-05
FI4222149T3 (fi) 2026-07-16
MX2023002900A (es) 2023-05-25
EP4222149B1 (en) 2026-05-06
AR123543A1 (es) 2022-12-14
ES3029607T3 (es) 2026-06-23
EP4781988A2 (en) 2026-07-29
LT4222149T (lt) 2026-08-10
AU2021353965A1 (en) 2023-04-27
CN116323601A (zh) 2023-06-23
IL301663A (en) 2023-05-01
PH12023550777A1 (en) 2023-11-20
RS68301B1 (en) 2026-07-31
ES3029607T1 (en) 2025-06-24
CA3196108A1 (en) 2022-04-07
ZA202302393B (en) 2026-03-25
CN116323601B (zh) 2026-05-12
EP3978487A1 (en) 2022-04-06
IL301663B2 (en) 2026-05-01
WO2022069509A1 (en) 2022-04-07
JP2023544716A (ja) 2023-10-25
BR112023004612A2 (pt) 2023-04-11
AU2021353965A9 (en) 2024-08-01
US12577230B2 (en) 2026-03-17
EP4222149A1 (en) 2023-08-09
JP7752684B2 (ja) 2025-10-10
IL301663B1 (en) 2026-01-01
DK4222149T3 (da) 2026-07-27